Gentamicin ( DrugBank: Gentamicin )


3 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa7
113Muscular dystrophy2
299Cystic fibrosis1

36. Epidermolysis bullosa


Clinical trials : 160 Drugs : 195 - (DrugBank : 47) / Drug target genes : 50 - Drug target pathways : 124
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04644627
(ClinicalTrials.gov)
December 1, 202020/11/2020Topical Gentamicin Nonsense Suppression Therapy of EBTOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONSEpidermolysis BullosaDrug: Gentamicin SulfateOslo University HospitalNULLRecruitingN/AN/AAll6Phase 1/Phase 2Norway
2EUCTR2020-002337-15-NO
(EUCTR)
16/09/202029/06/2020TOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSATOPICAL GENTAMICIN TREATMENT OF PATIENTS WITH EPIDERMOLYSIS BULLOSA DUE TO NONSENSE MUTATIONS (THE GENTELBULL STUDY) - GENTELBULL Epidermolysis bullosa caused by nonsense mutations or splice site mutations;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Infectogenta
Product Name: Gentamicin sulfate 0.1% ointment
Oslo University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Norway
3NCT04140786
(ClinicalTrials.gov)
October 31, 201923/10/2019Optimizing IV Gentamicin in JEBOptimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients With Nonsense MutationsJunctional Epidermolysis BullosaDrug: Gentamicin Sulfate, InjectableUniversity of Southern CaliforniaNULLRecruitingN/AN/AAll6Phase 1/Phase 2United States
4NCT03392909
(ClinicalTrials.gov)
July 5, 20182/1/2018Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin TreatmentRecessive Dystrophic Epidermolysis BullosaDrug: GentamicinUniversity of Southern CaliforniaNULLRecruiting7 YearsN/AAll9Phase 1/Phase 2United States
5NCT03526159
(ClinicalTrials.gov)
June 1, 201817/4/2018Gentamicin for Junctional Epidermolysis BullosaA Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin TreatmentJunctional Epidermolysis BullosaDrug: Gentamicin SulfateUniversity of Southern CaliforniaNULLRecruitingN/AN/AAll6Phase 1/Phase 2United States
6NCT03012191
(ClinicalTrials.gov)
February 2, 20174/1/2017Gentamicin for RDEBGentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense MutationsRecessive Dystrophic Epidermolysis BullosaDrug: Gentamicin SulfateUniversity of Southern CaliforniaNULLCompletedN/AN/AAll6Phase 1/Phase 2United States
7NCT02698735
(ClinicalTrials.gov)
February 25, 201619/2/2016Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation PatientsRecessive Dystrophic Epidermolysis BullosaDrug: Gentamicin;Drug: PlaceboUniversity of Southern CaliforniaNULLCompletedN/AN/AAll5Phase 1/Phase 2NULL

113. Muscular dystrophy


Clinical trials : 622 Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00451074
(ClinicalTrials.gov)
March 200721/3/2007Six Month Study of Gentamicin in Duchenne Muscular Dystrophy With Stop CodonsA Six Month Randomized, Clinical Trial of Gentamicin in Duchenne Muscular Dystrophy Subjects With Stop Codon MutationsDuchenne Muscular DystrophyDrug: Gentamicin infusions twice a week for six monthsNationwide Children's HospitalNational Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS)Completed5 Years20 YearsMale12Phase 1United States
2NCT00005574
(ClinicalTrials.gov)
February 20002/5/2000Gentamicin Treatment of Muscular DystrophyGentamicin Treatment of Patients With Muscular Dystrophy Due to Nonsense Mutations in DystrophinBecker Muscular Dystrophy;Duchenne Muscular DystrophyDrug: GentamicinNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompletedN/AN/ABoth4Phase 1United States

299. Cystic fibrosis


Clinical trials : 1,696 Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00376428
(ClinicalTrials.gov)
January 200313/9/2006Interest of Gentamicin-induced Readthrough in Cystic Fibrosis PatientsApplication of Functional Electrophysiological Tests to Evaluate Pharmacological Treatments in Patients With Cystic FibrosisCystic FibrosisDrug: GentamicinAssistance Publique - Hôpitaux de ParisNULLTerminatedN/AN/ABoth20Phase 2France